OBJECTIVES: The IMPROVE study includes results of 52,419 patient’s after 26 weeks of treatment with biphasic insulin aspart 30/70 (BIAsp30) in routine care setting. The aim of this  analysis was to project long-term clinical outcomes in patients with type 2 diabetes from the IMPROVE study switched from biphasic human insulin (BHI) to BIAsp30. METHODS: In total, 4,368 patients on BHI from the IMPROVE study were used in the present analysis. The CORE Diabetes Model was used to project long-term clinical outcomes based on the baseline characteristics (male 58.2%, mean age 57.0 years, duration of diabetes 10.7 years, HbA1c 9.2%, BMI 26.2 kg/m2 and total daily insulin dose 32.8 IU). Patients were assumed to either continue on BHI, or switch to BIAsp30 and obtain the significant (p≤0.01) treatment effects of BIAsp30 observed in the IMPROVE study (HbA1c improvement of 1.9 percentage points, 0.2 kg weight loss and 29.3 less major hypoglycemic events per 100 patient years).   RESULTS: The improved glycemic control resulting from a switch from BHI to BIAsp30 led to a projected delay in the onset of any diabetes-related complications of 0.7 years (2.0 versus 1.3, respectively). E.g. the projected delay of suffering a myocardial infarction was 1.7 for BIAsp30 and 1.4 years BHI. The cumulative incidence of complications was projected to decrease with BIAsp30 in the majority of parameters studied, e.g. the cumulative incidence of severe vision loss was projected to decrease by 8.5% (1.3 %-point absolute risk reduction) and strokes by 8.6% (1.1 %-point absolute risk reduction). The average life expectancy was projected to increase by 1.5 years. CONCLUSIONS: The long-term health outcome projections based on endpoints reported in the IMPROVE study indicate that switching patients with type 2 diabetes from BHI to BIAsp30 will improve life expectancy, delay the onset of diabetes-related complications, and reduce their cumulative incidence over patient lifetimes.